

# ctDNA Portfolio Development and Milestones



2018-2021

2022

2023 and beyond

KICKOFF

**FALL 2018**

ctDNA for monitoring treatment response discussed during the Friends' Annual Meeting.

STEP 2

**SPRING 2022**

Step 2 datasets finalized and include over 3000 patients from more than 20 clinical trials.

STEP 2

**WINTER 2023**

Planned analysis and submission of initial Step 2 findings for presentation in Q2

STEP 1

**SPRING 2019**

ctMoniTR Step 1 initiated to align on datasets and select an independent analysis center.

ROADMAP

**SPRING 2022**

Friends hosted roundtables to discuss evidentiary needs to support the regulatory use of ctDNA as an early endpoint.

STEP 2

**2023 AND BEYOND**

Complete analyses from Step 2. Present finalized results at meetings and publish manuscripts.

STEP 1

**SUMMER 2020**

Step 1 findings presented showing decreases in ctDNA are strongly associated with better clinical outcomes in 5 clinical trials of 200 patients with NSCLC treated with immunotherapy.

ROADMAP

**SUMMER 2022**

Public meeting held to present findings from the evidentiary roadmap.

ROADMAP

**2023 AND BEYOND**

Identify opportunities to incorporate analyses developed through ctMoniTR in additional prospective studies.

STEP 2

**SPRING 2021**

ctMoniTR Step 2 launched with a goal of developing and analyzing a larger dataset.

BASELINE

**FALL 2022**

Baseline ctDNA Project initiated to describe baseline ctDNA levels across cancer types, stages, and assays.

BASELINE

**2023 AND BEYOND**

Perform meta-analysis of baseline ctDNA levels and aid the use of ctDNA as an endpoint in different cancer types.

